Company intelligence / Profile preview
Senseion Therapeutics
St. Louis, Missouri, USAsenseion.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Senseion Therapeutics has advanced its lead small molecule candidate SN‑40X targeting chloride ion channels/LRRC8 proteins for metabolic diseases. The company has received multiple SBIR Phase I and II awards to support preclinical development, with promising results reported in glycemic control and prevention of vascular complications in type 2 diabetes. No clinical trial data yet available.[1][2][7]
- Therapeutic areas
- Metabolic DisordersEndocrinologyCardiovascularGastroenterology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Senseion Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Senseion Therapeutics.